Structure-Based Classification System for EGFR Mutations May Help Clinicians Personalize Treatments for More Patients
Xiuning Le, MD, PhD+more
Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations. Read more
After nearly 50 years of patient care at Rush University Medical Center, Dr. Bonomi will retire from his clinical service. Read more
Philip D. Bonomi, MD, who specializes in caring for those with lung cancer, has made many contributions to the field during his 47 years of service. Read more
More Robust Tools Needed to Predict who will Respond to Immune Checkpoint Inhibitors
Andrew McKenzie, PhDInvestigators at Sarah Cannon look to next-generation sequencing for molecular signatures that may correlate with response. Read more
See the latest IASLC meeting news, including an extended deadline for ACLC abstract submissions and COVID-19 guideline updates for those traveling to WCLC. Read more
Real-World Data from Taiwan Shows Stage Shift Has Improved Lung Cancer Survival Rates
Pan-Chyr Yang, MD, PhD+more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more
Comparable Efficacy, Disruptive Price for an Alternative EGFR TKI?
H. Jack West, MD+more
Aumolertinib may ultimately prove to be an alternative to osimertinib, but it faces challenges before it can win us fda approval. Read more
Lung Cancer Risk Prediction Model Demonstrates Readiness for Clinical Application
Andrea Borondy Kitts, MS, MPHEvidence demonstrates superior performance of the PLCOm2012 model for identifying individuals for lung cancer screening. Read more
Using Comparative Effectiveness Data Based on Non-Randomized Study Designs to Support Regulatory, Reimbursement Decision-Making
Sreeram Ramagopalan, PhDStudy provides evidence to support the potential role of real-world data in consideration of technologies where only single-arm trial data exists. Read more
In Measuring Outcomes, a Longer-Term View May be Needed
Mark Hennon, MD+more
When publicly reported patient outcomes emerge, the data available to patients should paint the most complete picture possible. Read more